Loading stock data…
$1.04-0.05 (-4.13%)
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases.
Telomir Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.04 with a market capitalization of $86M. Wall Street consensus targets $4.00 (1 analysts), implying a +282.8% move over the next 12 months. The stock is currently near its 52-week low of $0.89, remaining 16.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.76M↓ | -$1.04M↑ | -$2.13M↓ | -$1.15M↑ | -$5.07M |
| Net Income | -$1.72M↓ | -$990,947↑ | -$2.06M↓ | -$1.10M↑ | -$5.07M |
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral...